Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.

@article{Potosky2011UseOC,
  title={Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.},
  author={Arnold L. Potosky and Jennifer L. Malin and Benjamin Youngho Kim and Elizabeth A. Chrischilles and Solomon B. Makgoeng and Nadia Howlader and Jane C. Weeks},
  journal={Journal of the National Cancer Institute},
  year={2011},
  volume={103 12},
  pages={979-82}
}
Myeloid colony-stimulating factors (CSFs) decrease the risk of febrile neutropenia (FN) from high-risk chemotherapy regimens administered to patients at 20% or greater risk of FN, but little is known about their use in clinical practice. We evaluated CSF use in a multiregional population-based cohort of lung and colorectal cancer patients (N = 1849). Only 17% (95% confidence interval [CI] = 8% to 26%) patients treated with high-risk chemotherapy regimens received CSFs, compared with 18% (95% CI… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Insulin - like growth factor 1 receptor ( IGF 1 r ) expression in wild - type GIST : a potential novel therapeutic target

  • MA Pantaleo, A Astolfi, M DiBattista
  • Int J Cancer
  • 2009

Similar Papers

Loading similar papers…